Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1863 Lung Neoplasms 1292 Small Cell Lung Carcinoma 324 Colorectal Neoplasms 273 Breast Neoplasms 242 Melanoma 221 Neoplasms 215 Ovarian Neoplasms 192 Neoplasm Metastasis 182 Pancreatic Neoplasms 155 Squamous Cell Carcinoma of Head and Neck 150 Stomach Neoplasms 141 Head and Neck Neoplasms 121 Carcinoma, Renal Cell 119 Triple Negative Breast Neoplasms 109 Esophageal Neoplasms 108 Prostatic Neoplasms 106 Endometrial Neoplasms 98 Uterine Cervical Neoplasms 96 Urinary Bladder Neoplasms 87 Colonic Neoplasms 87 Mesothelioma 86 Mesothelioma, Malignant 80 Carcinoma, Hepatocellular 74 Brain Neoplasms 70 Sarcoma 63 Disease 62 Adenocarcinoma of Lung 59 Carcinoma, Transitional Cell 54 Gastrointestinal Neoplasms 50

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ALK+ Advanced NSCLC × Thoracic × 1 year × Clear all

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡